SCHEMBL2804986

SCHEMBL2804986

CCS(=O)(=O)NC1CCc2c(cnc3[nH]ncc23)C1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.35
DRD2 P14416 3/20 0.33
HTR2A P28223 3/20 0.33
DRD3 P35462 3/20 0.33
CA1 P00915 3/20 0.33
CA2 P00918 3/20 0.33
ACHE P22303 2/20 0.33
HPGDS O60760 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
CCNE2 O96020 1/20 0.33
CCNE1 P24864 1/20 0.33
CDK2 P24941 1/20 0.33
JAK1 P23458 2/20 0.32
TYK2 P29597 1/20 0.32
CYP11B1 P15538 1/20 0.31
CYP11B2 P19099 1/20 0.31
JAK3 P52333 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2802635 0.92 HDAC8 (0.38) PDE4BDRD2HTR2ADRD3CA1
SCHEMBL2803956 0.88 MAPK8 (0.36) PDE4BDRD2HTR2ADRD3CA1
SCHEMBL2805162 0.84 HPGDS (0.34) PDE4BCA1CA2ACHEHPGDS
SCHEMBL2804624 0.83 KIT (0.42) ALDH1A1
SCHEMBL2804709 0.81 ALDH1A1 (0.38) CA1CA2JAK1JAK3ALDH1A1
SCHEMBL2803517 0.81 RB1 (0.40) CA1CA2ACHEHDAC8ALDH1A1
SCHEMBL2804951 0.81 ALDH1A1 (0.44) ALDH1A1
SCHEMBL2489862 0.81 RB1 (0.43) DRD2HTR2ADRD3CA1CA2
SCHEMBL2802723 0.80 PAK1 (0.37) PDE4BCA1CA2ACHEALDH1A1
SCHEMBL2807827 0.79 PAK1 (0.36) CA1CA2ACHECCNE2CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 PDE4B 479/4885DRD2 2792/4885HTR2A 1862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.